Literature DB >> 3009202

Human natural killer cell lysis of virus-infected cells. Relationship to expression of the transferrin receptor.

L K Borysiewicz, S Graham, J G Sissons.   

Abstract

Natural killer (NK) cells lyse tumor and virus-infected cells yet the nature of the target structure they recognize is unknown. A normal host cell glycoprotein, the transferrin receptor (TfR), has been proposed as a target structure on tumor cells. We therefore investigated whether changes in the number or physiological recycling of the TfR, consequent on virus infection, were related to the differential susceptibility of virus-infected cells to NK lysis. There was a direct correlation between TfR expression, susceptibility to NK lysis and ability to act as cold target competitors, for human fibroblasts infected with RNA and DNA viruses (cytomegalovirus, herpes simplex, polio, vaccinia and Semliki Forest virus). The NK lysis of human cytomegalovirus-infected fibroblasts was studied in more detail. NK lysis was increased coincident with human cytomegalovirus early antigen expression and this susceptibility to lysis was associated with increased total and recycling TfR but only a slight increase in surface TfR expression. In addition, susceptibility of uninfected human fibroblasts to NK lysis directly correlated with TfR number. However, we were unable to inhibit NK lysis by either excess iron-saturated Tf or affinity-purified TfR. We conclude that there is a direct correlation between total TfR expression and susceptibility to NK lysis of human virus-infected cells; however, the NK target structure on virus-infected cells is probably not the TfR itself.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3009202     DOI: 10.1002/eji.1830160416

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  8 in total

Review 1.  Molecular biology and immunology of cytomegalovirus.

Authors:  P D Griffiths; J E Grundy
Journal:  Biochem J       Date:  1987-01-15       Impact factor: 3.857

2.  Natural killing of fibroblasts infected with low-passage clinical isolates of human cytomegalovirus.

Authors:  S Bandyopadhyay; S H Oh; S Michelson; D S Miller; J L Virelizier; S E Starr
Journal:  Clin Exp Immunol       Date:  1988-07       Impact factor: 4.330

Review 3.  The role of iron and iron binding proteins in lymphocyte physiology and pathology.

Authors:  J D Kemp
Journal:  J Clin Immunol       Date:  1993-03       Impact factor: 8.317

4.  Immediate-early gene expression is sufficient for induction of natural killer cell-mediated lysis of herpes simplex virus type 1-infected fibroblasts.

Authors:  P Fitzgerald-Bocarsly; D M Howell; L Pettera; S Tehrani; C Lopez
Journal:  J Virol       Date:  1991-06       Impact factor: 5.103

5.  Human cytomegalovirus-infected cells have unstable assembly of major histocompatibility complex class I complexes and are resistant to lysis by cytotoxic T lymphocytes.

Authors:  A P Warren; D H Ducroq; P J Lehner; L K Borysiewicz
Journal:  J Virol       Date:  1994-05       Impact factor: 5.103

Review 6.  Selective mechanisms utilized by persistent and oncogenic viruses to interfere with antigen processing and presentation.

Authors:  R Ehrlich
Journal:  Immunol Res       Date:  1995       Impact factor: 2.829

7.  Cytotoxic in vitro function in the lymphoproliferative disease of granular lymphocytes.

Authors:  R Zambello; T Chisesi; C Agostini; L Trentin; M Masciarelli; G Gasparotto; M Vespignani; G Casorati; R Foa; G Semenzato
Journal:  Clin Exp Immunol       Date:  1987-10       Impact factor: 4.330

Review 8.  Bracing NK cell based therapy to relegate pulmonary inflammation in COVID-19.

Authors:  Madhan Jeyaraman; Sathish Muthu; Asawari Bapat; Rashmi Jain; E S Sushmitha; Arun Gulati; Talagavadi Channaiah Anudeep; Shirodkar Jaswandi Dilip; Niraj Kumar Jha; Dhruv Kumar; Kavindra Kumar Kesari; Shreesh Ojha; Sunny Dholpuria; Gaurav Gupta; Harish Dureja; Dinesh Kumar Chellappan; Sachin Kumar Singh; Kamal Dua; Saurabh Kumar Jha
Journal:  Heliyon       Date:  2021-07-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.